\nAlpha Cognition Inc. (Nasdaq: ACOG) (\u201cAlpha Cognition\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists (AAGP), taking place April 16-20, 2026 and the Neuroscience Education Institute (NEI) Spring Congress, taking place May 1-3, 2026.<\/p>\n
\nThe Company will share the following poster presentations:<\/p>\n
Beyond Cholinesterase Inhibition: The Clinical Benefits of Galantamine- and Benzgalantamine-Mediated Nicotinic Receptor Modulation in Alzheimer\u2019s Disease
\n
<\/b>Presenter: Kurt Grady, PharmD (Poster S49)
\n
Presentation: April 18, 5:30pm EST<\/p>\n
Literature Review: Acetylcholinesterase Inhibitors and Delayed Nursing Home Placement in Alzheimer\u2019s Disease
\n
<\/b>Presenter: Pavel Svintozelskiy, PharmD (Poster S45)
\n
Presentation: April 18, 5:30pm EST<\/p>\n
Acetylcholinesterase Inhibitors and Psychotropic Medication Use in Alzheimer\u2019s Disease and Related Dementias (ADRD)
\n
<\/b>Presenter: Pavel Svintozelskiy, PharmD
\n
Presentation: May 2, 9:45am EST<\/p>\n
Acetylcholinesterase Inhibitor Persistence: The Value of Sustained Therapy in Alzheimer\u2019s Disease and Related Dementias
\n
<\/b>Presenter: Kurt Grady, PharmD
\n
Presentation: May 2, 9:45am EST<\/p>\n
\n\u201cWe\u2019re excited to present new data on ZUNVEYL at these upcoming conferences, further characterizing its clinical profile in patients with Alzheimer\u2019s disease,\u201d said Dennis Kay, PhD, Chief Scientific Officer of Alpha Cognition. \u201cThese findings build on our understanding of ZUNVEYL\u2019s potential and reinforce our commitment to improving outcomes for patients and caregivers through innovative approaches. We look forward to engaging with the scientific and medical community as we continue to support its integration into real-world treatment settings.\u201d<\/p>\n
About Alpha Cognition Inc.<\/b><\/p>\n
\nAlpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer\u2019s disease and cognitive Impairment with mild Traumatic Brain Injury (\u201cmTBI\u201d), for which there are currently no approved treatment options.<\/p>\n
\nALPHA-1062 formulated as a delayed release oral tablet (ZUNVEYL), is an FDA approved new generation acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease, with expected minimal gastrointestinal side effects. ZUNVEYL\u2019s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer\u2019s dementia, and as a sublingual formulation for cognitive Impairment with mTBI.<\/p>\n
INDICATION AND USAGE<\/b><\/p>\n
\nZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer\u2019s type in adults.<\/p>\n
IMPORTANT SAFETY INFORMATION<\/b><\/p>\n
CONTRAINDICATIONS<\/b><\/p>\n
\nZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred.<\/p>\n
WARNINGS AND PRECAUTIONS<\/b><\/p>\n
Serious Skin Reactions<\/b>: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered.<\/p>\n
Anesthesia<\/b>: See Drug Interactions Section<\/p>\n
Cardiovascular Conditions:<\/b> Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction.<\/p>\n
\nPatients treated with galantamine up to 24 mg\/day using the recommended dosing schedule showed a dose-related increase in risk of syncope.<\/p>\n
Gastrointestinal Conditions<\/b>: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.<\/p>\n
\nGalantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. <\/i>Monitor the patient’s weight during therapy with ZUNVEYL.<\/p>\n
Genitourinary Conditions:<\/b> Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction.<\/p>\n
Neurological Conditions:<\/b> Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer’s disease. Patients with Alzheimer’s disease should be monitored closely for seizures while taking ZUNVEYL.<\/p>\n
Pulmonary Conditions:<\/b> Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions.<\/p>\n
ADVERSE REACTIONS<\/b><\/p>\n
\nThe most common adverse reactions with galantamine tablets (\u22655%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.<\/p>\n
DRUG INTERACTIONS<\/b><\/p>\n
Use with Anticholinergics:<\/b> Galantamine has the potential to interfere with the activity of anticholinergic medications.<\/p>\n
Use with Cholinomimetics and Other Cholinesterase Inhibitors:<\/b> A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.<\/p>\n
USE IN SPECIFIC POPULATIONS<\/b><\/p>\n
Pregnancy: <\/b>Based on animal data may cause fetal harm.<\/p>\n
Hepatic Impairment:<\/b> In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended.<\/p>\n
Renal Impairment:<\/b> In patients with a creatinine clearance of 9 to 59 mL\/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL\/min is not recommended.<\/p>\n
\nThese are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov\/MedWatch<\/a> or call 1\u2011800\u2011FDA\u20111088. Please click here for Full Prescribing Information<\/a>.<\/p>\n Forward-looking Statements<\/b><\/p>\n \nThis news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward\u2010looking statement that reflects the Company\u2019s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward\u2010looking statements by the words \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cobjective,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201ccontinue\u201d and \u201congoing,\u201d or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward\u2010looking statements may include statements regarding the, the long-term benefits of ZUNVEYL, the Company\u2019s timing and planned activities and business strategy to launch ZUNVEYL, the potential timing for the availability of ZUNVEYL, the potential future developments of ZUNVEYL, the market size and demand for ZUNVEYL and the Company\u2019s potential growth opportunities, capital requirements,. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks related to our focus on the long-term care market, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company\u2019s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company\u2019s filings with Canadian securities regulatory authorities and available at www.sedar.com<\/a> and the Company\u2019s filings with the United States Securities and Exchange Commission (the \u201cSEC\u201d), including those risk factors under the heading \u201cRisk Factors\u201d in the Company\u2019s Form S-1\/A registration statement as filed with the SEC on January 10, 2025 and available at www.sec.gov<\/a>. These forward\u2010looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward\u2010looking statements for any reason, even if new information becomes available in the future, except as required by law.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260310594648\/en\/<\/a><\/span><\/p>\n \nFor further information: \nLifeSci Advisors, PJ Kelleher KEYWORDS:<\/b> Texas United States North America Canada<\/p>\n INDUSTRY KEYWORDS:<\/b> Health Neurology Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<\/p>\n
\n
Investor Relations
\n
IR@alphacognition.com
\n<\/a>
https:\/\/www.alphacognition.com\/<\/a><\/p>\n
\n
pkelleher@lifesciadvisors.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260310594648\/en\/2740215\/3\/Alpha_Cognition_Logo_2025_4C.jpg\"){kind=logo}
<\/td>\n<\/tr>\n